“The introduction of gene editing and CRISPR-based approaches in the clinic will likely begin with T-cell therapies because of the relative ease of T-cell manipulation and transduction, combined with the relevance of T-cell therapies to a large number of disorders, including cancer and others.” ~ Dr. Michel Sadelain, MD, Ph.D.
Dr. Michel Sadelain, MD, PHD,
reinventing the world's food stream one gene at a time
Recent posts
-
First human transplant of a genetically modified pig kidney performed
The kidney transplanted in Boston came from a…Read more -
Novel treatment based on gene editing safely and effectively removes HIV-like virus from genomes of non-human primates
A single injection of a novel CRISPR gene-editing…Read more
admin
admin
admin